ArticleFrontiers in immunology2022

Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.

Yu-Xiang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.